<DOC>
	<DOCNO>NCT00003842</DOCNO>
	<brief_summary>RATIONALE : IL-4 ( 38-37 ) -PE38KDEL immunotoxin may locate tumor cell kill without harm normal cell . This may effective treatment recurrent malignant astrocytoma . PURPOSE : Phase I trial study effectiveness IL-4 ( 38-37 ) -PE38KDEL immunotoxin treat patient recurrent malignant astrocytoma .</brief_summary>
	<brief_title>IL-4 ( 38-37 ) -PE38KDEL Immunotoxin Treating Patients With Recurrent Malignant Astrocytoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intratumorally infused IL-4 ( 38-37 ) -PE38KDEL immunotoxin patient recurrent malignant astrocytoma . II . Determine safety regimen patient . III . Determine preliminarily efficacy regimen patient . OUTLINE : This dose escalation , multicenter study . Patients undergo stereotactic biopsy MR/CT guidance . Catheters place tumor stereotactic guidance . The catheter fill IL-4 ( 38-37 ) -PE38KDEL immunotoxin ( IL-4 toxin ) , infusion begin 24 hour catheter insertion . The IL-4 toxin infuse 4 day . The catheter remove 45 minute infusion complete MR scan perform . Cohorts 3 patient receive escalate dos IL-4 toxin maximum tolerate dose ( MTD ) reach . The MTD define dose precede dose 2 3 patient experience dose limit toxicity . Patients follow every 4 week 16 week , every 8 week 3 year . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent glioblastoma anaplastic astrocytoma Stereotactically accessible , enhance mass great 50 mL total volume MRI No significant mass effect Recent craniotomy allow No anaplastic oligodendroglioma No tumor brainstem , cerebellum , hemispheres No diffuse subependymal CSF disease If stable increase dose steroid , must evidence increase contrast enhancement MRI CT scan Prior external beam radiotherapy require PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9.5 g/dL Hepatic : Bilirubin le 2 mg/dL AST ALT less 2 time upper limit normal ( ULN ) PT/PTT great ULN Renal : Creatinine le 2 mg/dL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No systemic disease cause unacceptable anesthetic/operative risk No active infection require treatment No unexplained febrile illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent blood platelet transfusion Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Medically able undergo surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>